The Cost of Alzheimerʼs Disease
- 1 January 1996
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 9 (1), 5-10
- https://doi.org/10.2165/00019053-199609010-00002
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- The US economic and social costs of Alzheimer's disease revisited.American Journal of Public Health, 1994
- Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trialBMJ, 1994
- Expenditures in caring for patients with dementia who live at home.American Journal of Public Health, 1993
- A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's DiseaseNew England Journal of Medicine, 1992
- Tacrine in Alzheimer's diseaseThe Lancet, 1991
- Tetrahydroaminoacridine–Lecithin Combination Treatment in Patients with Intermediate-Stage Alzheimer's DiseaseNew England Journal of Medicine, 1990
- Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Francais d'Etude de la Tetrahydroaminoacridine.BMJ, 1990
- TACRINE IN ALZHEIMER'S DISEASEThe Lancet, 1989
- Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer TypeNew England Journal of Medicine, 1986
- Evaluation of the Costs of Caring for the Senile Demented Elderly: A Pilot StudyThe Gerontologist, 1986